Achieving targeted patient outcomes is the key to market success for innovator drugs in today’s challenging market access and reimbursement environment. Most innovator drugs have been approved for a broad range of adolescent and adult patients, and a small but growing share for younger pediatric patients as well. But a growing body of modern research – and nearly two millennia of pre-industrialized medicine – clearly demonstrates that different patient groups could benefit from differences in drug product design. Age-related ADME differences, cultural norms, concomitant conditions, and involvement of caregivers in treatment are among the many factors that indicate that patient outcomes may be enhanced by targeted drug product design. This panel will focus on two age-defined population groups with unique delivery challenges, pre-adolescent pediatric and geriatric patients, and will also offer a physician/payor perspective on other population groups that might benefit from modifications in drug product design to enhance patient outcomes.
Rachel S. Meyers, PharmD, BCPS, BCPPS; Clinical Associate Professor, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey; Pediatric Pharmacist, Saint Barnabas Medical Center
Judith L. Beizer, PharmD, BCGP, FASCP, AGSF; Clinical Professor, College of Pharmacy & Health Sciences, St. John’s University
Edmund Pezalla, MD, MPH; Founder and CEO, Enlightenment Bioconsult, LLC; formerly VP, Pharmaceutical Policy and Strategy, Aetna; Fellow-in-Residence, Duke Margolis Center for Health Policy, and member of MIT NEWDIGS Project
Cornell Stamoran, Ph.D.; Vice President, Corporate Strategy, Catalent Pharma Solutions; Founder and co-Chair, Catalent Applied Drug Delivery Institute